These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 22610729)

  • 1. Cancer therapy with genetically-modified T cells for the treatment of melanoma.
    Lagisetty KH; Morgan RA
    J Gene Med; 2012 Jun; 14(6):400-4. PubMed ID: 22610729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.
    Coccoris M; Straetemans T; Govers C; Lamers C; Sleijfer S; Debets R
    Expert Opin Biol Ther; 2010 Apr; 10(4):547-62. PubMed ID: 20146634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically modulating T-cell function to target cancer.
    Merhavi-Shoham E; Haga-Friedman A; Cohen CJ
    Semin Cancer Biol; 2012 Feb; 22(1):14-22. PubMed ID: 22210183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
    Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
    Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-cistronic vector encoding optimized safety switch for adoptive therapy with T-cell receptor-modified T cells.
    van Loenen MM; de Boer R; Hagedoorn RS; Jankipersadsing V; Amir AL; Falkenburg JH; Heemskerk MH
    Gene Ther; 2013 Aug; 20(8):861-7. PubMed ID: 23364317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma production.
    Schaft N; Lankiewicz B; Drexhage J; Berrevoets C; Moss DJ; Levitsky V; Bonneville M; Lee SP; McMichael AJ; Gratama JW; Bolhuis RL; Willemsen R; Debets R
    Int Immunol; 2006 Apr; 18(4):591-601. PubMed ID: 16507598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen.
    Cole DJ; Weil DP; Shilyansky J; Custer M; Kawakami Y; Rosenberg SA; Nishimura MI
    Cancer Res; 1995 Feb; 55(4):748-52. PubMed ID: 7531614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene transfer of human TCR in primary murine T cells is improved by pseudo-typing with amphotropic and ecotropic envelopes.
    Pouw NM; Westerlaken EJ; Willemsen RA; Debets R
    J Gene Med; 2007 Jul; 9(7):561-70. PubMed ID: 17471588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell engineering for cancer immunotherapy.
    Sadelain M
    Cancer J; 2009; 15(6):451-5. PubMed ID: 20010162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identical T-cell receptor transcripts in multiple melanoma metastases.
    Schrama D; Fuchs E; Bröcker EB; Thor Straten P; Becker JC
    Cancer Res; 2002 Oct; 62(20):5664-7. PubMed ID: 12384521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study.
    Sun Y; Jurgovsky K; Möller P; Alijagic S; Dorbic T; Georgieva J; Wittig B; Schadendorf D
    Gene Ther; 1998 Apr; 5(4):481-90. PubMed ID: 9614572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer. Cancer immunotherapy is more than a numbers game.
    Offringa R
    Science; 2006 Oct; 314(5796):68-9. PubMed ID: 17023641
    [No Abstract]   [Full Text] [Related]  

  • 14. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.
    Berry LJ; Moeller M; Darcy PK
    Tissue Antigens; 2009 Oct; 74(4):277-89. PubMed ID: 19775368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic.
    Eshhar Z
    Curr Opin Mol Ther; 2010 Feb; 12(1):55-63. PubMed ID: 20140817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selected murine residues endow human TCR with enhanced tumor recognition.
    Bialer G; Horovitz-Fried M; Ya'acobi S; Morgan RA; Cohen CJ
    J Immunol; 2010 Jun; 184(11):6232-41. PubMed ID: 20427762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redirecting T lymphocyte specificity by T cell receptor gene transfer--a new era for immunotherapy.
    Engels B; Uckert W
    Mol Aspects Med; 2007 Feb; 28(1):115-42. PubMed ID: 17307249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is adoptive T-cell therapy for solid tumors coming of age?
    Pedrazzoli P; Comoli P; Montagna D; Demirer T; Bregni M;
    Bone Marrow Transplant; 2012 Aug; 47(8):1013-9. PubMed ID: 21804611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation.
    Burns WR; Zheng Z; Rosenberg SA; Morgan RA
    Blood; 2009 Oct; 114(14):2888-99. PubMed ID: 19589923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.